A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer
A Phase 1 study of IBI363 in combination with Bevacizumab or Furuitinib in Subjects with Advanced Colorectal Cancer
Trial Details
- NCT ID
- NCT06717880
- Phase
- PHASE1
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Status
- RECRUITING
- Cancer Type
- Colorectal Cancer
- Interventions
- IBI363 combined with Bevacizumab
- IBI363 + Furuitinib
- Locations (sample)
- Wuhan, Hubei, China|30.58333,114.26667
Key Eligibility Criteria
- Sign written informed consent and be able to comply with the program's visit schedule and related procedures.
- Male or female subjects, age 18\~75 years.
- Histologically or cytologically confirmed advanced colorectal cancer.
- Subjects who have progressed on standard therapy, who are unsuitable for standard therapy, who do not have standard therapy, or who have refused st…
For full eligibility, visit ClinicalTrials.gov.